After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs scheduled for the first week of November, though it is...read more
Seven IPOs and 10 SPACs went public this past week. The IPO pipeline remained active, with 11 IPOs and 22 SPACs submitting initial filings. Phase 2 biotech Kronos Bio (KRON) priced above the range to raise $250 million at a $1.1 billion...read more
Shattuck Labs, a Phase 1 biotech developing novel dual-sided fusion protein therapies for cancer, raised $202 million by offering 11.9 million shares at $17, above the range of $14 to $16. The company offered 1.9 million more shares than anticipated. At pricing,...read more
Shattuck Labs, a Phase 1 biotech developing dual-sided fusion protein therapies for cancer, announced terms for its IPO on Monday. The Austin, TX-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the...read more
US IPO Week Ahead: Hot IPO market takes a break for election week
After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs scheduled for the first week of November, though it is...read more
US IPO Weekly Recap: Healthcare dominates a 7 IPO week
Seven IPOs and 10 SPACs went public this past week. The IPO pipeline remained active, with 11 IPOs and 22 SPACs submitting initial filings. Phase 2 biotech Kronos Bio (KRON) priced above the range to raise $250 million at a $1.1 billion...read more
Oncology biotech Shattuck Labs prices upsized IPO above the range at $17
Shattuck Labs, a Phase 1 biotech developing novel dual-sided fusion protein therapies for cancer, raised $202 million by offering 11.9 million shares at $17, above the range of $14 to $16. The company offered 1.9 million more shares than anticipated. At pricing,...read more
Oncology biotech Shattuck Labs sets terms for $150 million IPO
Shattuck Labs, a Phase 1 biotech developing dual-sided fusion protein therapies for cancer, announced terms for its IPO on Monday. The Austin, TX-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the...read more